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Abstract
After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human 
syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical 
studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency 
or pharmacological neutralization increases bone formation. Dysregulation of sclerostin 
expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone 
mass as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly 
become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, 
and beneficial skeletal outcomes are observed in animal studies and clinical trials using 
neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin 
decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is 
bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the 
bone/bone marrow microenvironment under physiological and pathological conditions, the 
pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates 
the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight 
the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of 
action, discuss novel observations regarding its role in signaling pathways activated by hormones 
and mechanical stimuli in bone, and propose future research needed to understand the full 
potential of therapeutic interventions that modulate Sost/sclerostin expression.
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1. SOST/SCLEROSTIN, CANONICAL WNT SIGNALING, AND BONE MASS
A critical advance in our understanding of skeletal biology of the last few years was the 
discovery of the role of Wnt/βcatenin signaling in bone (1). Wnt/βcatenin signaling is 
activated by binding of Wnt proteins to receptor complexes composed of frizzled receptors 
and co-receptors of the low density lipoprotein receptor-related protein (LRP) family, LRP5 
and 6. This event stabilizes βcatenin, induces its translocation to the nucleus, and activates 
gene transcription. This so-called canonical Wnt signaling pathway controls differentiation 
of mesenchymal stem cells (MSC) restraining chondrogenic and adipogenic differentiation 
and favoring osteoblastic differentiation. Canonical Wnt signaling also promotes osteoblast 
maturation and survival of osteoblasts and osteocytes, and inhibits osteoclast generation by 
increasing the expression in osteoblasts and osteocytes of osteoprotegerin (Opg), the decoy 
receptor of the receptor activator of Nfκb ligand (Rankl). Thus, activation of this pathway is 
critical for bone acquisition and maintenance through increased bone formation and 
decreased resorption.
Osteocytes are key players in the regulation of the canonical Wnt signaling pathway as 
producers and targets of Wnt ligands and as secretors of molecules that modulate Wnt 
actions (1;2). A potent antagonist of Wnt signaling secreted by osteocytes is sclerostin, a 
protein encoded by the Sost gene primarily expressed by mature osteocytes but not by early 
osteocytes or osteoblasts (3). Sclerostin binds to the Wnt co-receptors LRP5/6 antagonizing 
downstream signaling (4). Sclerostin also interacts with LRP4, another member of the LRP 
family of proteins, which acts as a chaperone and is required for the inhibitory action of 
sclerostin on Wnt/βcatenin signaling (5).
Absence of sclerostin expression or secretion in humans causes inherited high bone mass 
conditions characterized by exaggerated bone formation, including sclerosteosis, van 
Buchem disease, and craniodiaphyseal dysplasia (1). Consistent with the requirement of 
LRP4 for the inhibitory function of sclerostin, individuals with LRP4 inactivating mutations 
exhibit high bone mass. Moreover, genetic deletion of Sost or LRP4 in mice or neutralizing 
antibodies for sclerostin or LRP4 reproduce the high bone mass phenotype found in humans 
lacking sclerostin or LRP4 activity (6–10). In contrast, overexpression of Sost/sclerostin 
decreases bone mass (11–14). In addition, mice expressing LRP5 mutants with deficient 
binding to sclerostin exhibit high bone mass, demonstrating a central role of the inhibitory 
action of sclerostin in the modulation of bone maintenance (13).
2. SOST/SCLEROSTIN EXPRESSION AND ITS REGULATION
Cellular sources of Sost/sclerostin
Immunohistochemical approaches performed in human and rodent bone demonstrate that 
sclerostin is expressed in osteocytes, but not in osteoblasts or lining cells. Consistent with 
being a secreted protein, sclerostin is detected in osteocytic lacunae and along osteocytic 
canaliculi. Sost/sclerostin is a marker of mature osteocytes and its expression progressively 
increases as osteocytes mature and acquire their full molecular signature (15). Thus, 
sclerostin is rarely detected in recently embedded osteocytes (osteoid osteocytes) or in 
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osteocytes close to bone forming surfaces. In contrast, high levels of sclerostin are found in 
osteocytes surrounded by mineralized bone and distant from active bone surfaces (3;16–18).
Although the current evidence indicates that sclerostin is predominately produced by 
osteocytes in bone in the adult skeleton, new studies suggest that other cells of bone and the 
bone microenvironment might express the Sost gene in the developing skeleton or under 
pathological conditions. Recently, mice expressing Cre recombinase under the control of the 
second exon of the murine Sost gene (Sost-Cre mice) were crossed with Cre-reporter mice 
expressing tdTomato fluorescent protein. The progeny of this cross exhibited tdTomato 
expression in osteocytes, but not osteoblasts or lining cells, confirming the osteocyte-specific 
expression of Sost (19). However, reporter gene activation was also observed in bone 
marrow cells of the hematopoietic lineage, although Sost mRNA expression was not 
detected in the marrow (19). This apparent contradiction could be explained by transient 
expression of the Sost-Cre transgene in marrow cells during the mouse development, which 
resulted in Cre-mediated expression of the fluorescent protein. These findings highlight that 
interpretation of studies using Cre-reporter mice is challenging because a Cre-mediated 
recombination event at an earlier time point persists in all daughter cells, regardless of 
whether these cells continue to express Cre. Moreover, they caution that the spatiotemporal 
profile of Cre expression by examination of reporter gene expression needs to be validated 
by detecting mRNA/protein expression of the actual gene of interest in targeted tissues.
Sost/Sclerostin expression has been also detected in bone marrow derived-osteoclast 
precursors and found to decrease as osteoclasts are formed in vitro (20). In addition, higher 
levels of sclerostin are produced by osteoclast cultures established from bone marrow of old 
compared to young mice, suggesting that osteoclast-derived sclerostin may contribute to the 
decrease in bone formation that ensues with aging (21). Sclerostin-positive osteoblasts, 
cementocytes and mineralized hypertrophic chondrocytes have been reported in different 
studies (22–25). However, some of these studies lack proper controls and thus the biological 
relevance of these findings is uncertain. Sclerostin has also been detected in calcifying 
vascular tissues (26–28). Moreover, fibroblast-like synoviocytes have been also proposed to 
be a major source of sclerostin in rheumatoid arthritis (29), and multiple myeloma cells 
appear to also express the protein (30;31), as it will be discussed below. All this evidence 
notwithstanding, the contribution of non-osteocytic sclerostin to the skeletal effects 
attributed to this protein remains to be determined.
Regulation of Sost transcription and sclerostin synthesis
Sclerostin is encoded by Sost, a gene identified through genetic linkage analyses in 
sclerosteosis and van Buchem’s disease patients (7;32). It is now recognized that several 
regulatory elements in the Sost gene tightly regulate its transcription in bone. The first 
evidence of a mechanism regulating Sost transcription derived from the observation that Van 
Buchem’s patients exhibit a homozygous deletion of a 52-kb noncoding located 35 kb 
downstream of the SOST transcription start site (33;34). This finding led to the identification 
of an enhancer element essential for Sost expression, evolutionarily conserved region 5 
(ECR5), and the regulation of Sost transcriptional activity by myocyte enhancer factor-2 
(Mef2c), a transcription factor that binds to ECR5 (35;36).
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Growing evidence supports that epigenetic modifications in the Sost proximal promoter 
(~1.4Kb upstream the SOST gene) also control expression of this gene, one of them being 
DNA methylation (37). Accumulation of DNA methyl marks in the proximal promoter of 
Sost prevents binding of transcription factors and inhibits Sost gene expression in 
osteoblasts (38). Conversely, elimination of DNA methyl marks during osteoblast-osteocyte 
transition allows osteocytes to express the gene (38). In addition, sirtuin 1, a histone 
deacetylase (HDAC) that remodels chromatin to silence gene expression, directly and 
negatively regulates Sost gene expression by deacetylation of histone 3 at lysine 9 at the Sost 
promoter (39). In contrast, silencing of class I HDACs 1, 2, and 3 inhibits constitutive 
expression of Sost (40), suggesting that different HDACs can have different actions on Sost 
expression. Taken together these findings suggest that Sost expression is regulated by 
epigenetic mechanisms that act as an on-off switch to restrict the expression of this gene to 
particular cell types.
A number of transcription factors activated in response to cytokines and growth factors also 
bind to regulatory regions of the Sost gene. Sost transcription is negatively regulated by 
parathyroid hormone (PTH) as discussed below, via HDAC5 and Mef2c through interactions 
with response elements located in the ECR5 regulatory region (35;41–43). In addition, 
Smads can bind to ECR5 and mediate the regulation of Sost expression by transforming 
growth factor beta and activin-A (44), and most likely bone morphogenetic proteins (44–46). 
Osterix and Runx2 also bind to response elements located upstream of the Sost transcription 
start site and are positive regulators of Sost/sclerostin production (47); whereas osteocytes 
cultured under hypoxia exhibit decreased Sost and sclerostin expression (48). Moreover, 
mechanical loading negatively regulates Sost expression by mechanisms that might involve 
prostaglandin E2 production, nitric oxide, and periostin expression (11;49–51). In vitro 
studies using a reporter construct carrying the proximal Sost promoter also identified 
forskolin and oncostatin M as potential regulators of Sost expression (52;53). In addition to 
PTH, other systemic hormones have a strong impact on Sost regulation. Androgens and 
estrogens inhibit Sost expression (54;55), although the mechanisms are still unclear. In 
contrast, excess of glucocorticoids increases Sost and sclerostin production in osteocytes 
(56), as will be discussed below. Vitamin D can also regulate Sost expression, although 
contradictory data has been published. Thus, using Saos-2 cells, Wijenayaka et al showed 
that 1α,25-dihydroxyvitamin D3 induces the expression of Sost/Sclerostin (57), whereas St 
John et al found that it decreases the transcriptional activity of the Sost promoter (52). 
Similarly conflicting clinical data on the effects of vitamin D status on circulating sclerostin 
levels have been reported (58–62). Furthermore, tumor necrosis factor alpha and Tnf-related 
weak inducer of apoptosis increase Sost expression (63). In addition, glucose and advanced 
glycation end products increase Sost expression in vitro (64), and Sost/sclerostin expression 
is increased in mice with diabetes type 1 (65).
Unresolved enigmas in the study of the Sost/sclerostin regulation
The mechanisms controlling osteoblast differentiation towards mature osteocytes remain 
unclear. In vitro osteoblast to osteocyte differentiation is complex and give rise to cell 
populations with few of osteocytes, even after long periods of culture. Thus, one of the 
problems faced when studying the mechanisms regulating Sost expression is the limitations 
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of the cellular systems used for in vitro studies. Initial experiments were done with the rat 
UMR-106 cells (66;67) and human Saos-2 cells (68;69), which constitutively express Sost/
sclerostin. However, the fact that these cells are derived from osteosarcoma limit the impact 
and interpretation of the results. Cell lines established from murine bone were developed and 
have been extensively used, but also present limitations. The murine MLO-Y4 and MLO-A5 
cells exhibit very low expression of Sost/sclerostin and the IDG-SW3 and Ocy454 cells 
require several days of culture to achieve detectable Sost mRNA transcripts and sclerostin 
protein (70–72). Human osteoblastic cell lines capable to differentiate and express Sost/
Sclerostin in vivo have been established (73) and artificial expression of Sost/Sclerostin has 
been achieved in human dermal fibroblasts (74). These approaches might prove useful in the 
future. An alternative to the cell lines is the use of ex vivo bone organ cultures in which the 
tridimensional living structure of the osteocyte network is maintained. This approach 
recapitulates closely the in vivo responses of Sost (and other osteocytic genes) to PTH, 
glucocorticoids and Wnt/βcatenin (56;75;76).
The exact mechanisms controlling sclerostin protein synthesis remain unclear. Sclerostin 
was originally described as a glycoprotein of ~27 KDa that is secreted in a monomeric form 
(77;78). However, sclerostin is rarely detected at this molecular weight; instead higher 
molecular weight forms are found, potentially dimers and trimers, although their functions 
are yet to be determined (79). Moreover, there is poor correlation between mRNA Sost 
levels and sclerostin protein expression. For instance, Sost gene expression has been 
detected in other organs besides bone, such as kidney, lung, heart, and aorta; however, 
sclerostin protein is rarely detected in these tissues (7;78). In fact, although the ECR5 is 
required for a normal production of Sclerostin by osteocytes in bone, it does not contribute 
to the regulation of Sclerostin expression in cells from other tissues (i.e. kidney, lung, or 
aorta) suggesting that tissue-specific mechanisms may regulate the expression of this gene 
(36).
Another unresolved issue regarding the Sost/sclerostin system is that the Sost/sclerostin 
expression levels in bone do not always correlate with sclerostin levels in the circulation. For 
example, serum sclerostin increases with age in humans, but Sost mRNA levels in bone are 
not different between old and young subjects (80;81). Similarly, sclerostin is high in the 
serum of osteoporotic patients, whereas no differences in Sost mRNA or sclerostin 
expression in bone are detected between normal and osteoporotic subjects (16;58;82). Some 
of these discrepancies may reflect limitations of the available assays used to measure 
sclerostin or differences in the material used in the analysis (serum versus plasma) (83). 
Nevertheless, these inconsistencies question the value of relying on circulating sclerostin 
levels to predict bone formation or bone mass. A clear example of this dichotomy is 
represented by the aforementioned genetic deletion of LRP4 from the mouse genome. LRP4 
KO mice exhibit increased bone formation and mass despite the high levels of serum 
sclerostin (9;84), confirming that local rather than circulating sclerostin levels better reflect 
the skeletal actions of the protein. In contrast, another study reported that high levels of 
sclerostin in the blood achieved by using the ΦC31 integrase system to overexpress the 
protein, resulted in trabecular bone loss (85). Further research to unravel how sclerostin 
production is controlled and to determine the local versus systemic actions of the protein is 
needed.
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3. SOST/SCLEROSTIN FUNCTION
Sost/sclerostin potently inhibits bone formation
Studies with genetically modified mice provided insights into the mechanism of action of 
Sost/sclerostin in bone. Deletion of the Sost gene from the murine genome reproduced the 
high bone mass hallmark of humans with inheritable sclerostin deficiency as in cases of 
sclerosteosis or Van Buchem disease (5;7;8;86). This phenotype is driven by increased bone 
formation on all bone surfaces, without changes in osteoclasts or resorption markers 
compared to age-matched wild type (WT) mice (8). The anabolic effect of Sost deletion 
(Sost KO) results in up to >50% gain in vertebral and long bone BMD in mice of both 
genders and enhanced structural properties in cancellous and cortical bone. In contrast to 
high bone mass phenotypes due to osteopetrosis that present with increased bone fragility 
and compromised material properties, the gain in bone mass in the Sost KO mice results in 
increased structural material properties of maximum load, stiffness, and energy to failure (8). 
Increased strength of sclerostin deficient bones might be, at least in part, due to favorable 
alterations in bone composition, as bones from Sost KO and sclerosteosis patients have 
enhanced relative proteoglycan content, lower apatite crystal maturity/crystallinity, and 
lower matrix mineralization (87), all properties associated with increased toughness and 
decreased brittleness.
Conversely, mice overexpressing Sost exhibit overall suppressed bone formation resulting in 
notable reductions of bone mass and volume (12;33;77). However, some differences are 
found depending on the promoter used to overexpress the gene. Thus, when the human 
osteocalcin promoter was used, the osteopenic phenotype was observed in cancellous bone 
and it was accompanied by increased chondrodysplasia as evidenced by lack of lamellar 
bone formation with increased hypertrophic chondrocyte and calcified cartilage area (77). 
Reduced appositional bone and increased osteoid was also observed in calvarial bone. 
Consequently, marked decreased bone strength was exhibited in lumbar vertebra, femoral 
head, and the whole femur (77). Mice overexpressing a transgene in which Sost is driven by 
the entire human SOST promoter (BAC-SOST mice) also displayed reduced cancellous 
bone of the axial and appendicular skeleton due to reductions in bone formation (14;33;77). 
In addition, these mice, as well as mice expressing a transgene with a Van Buchem’s like 
deletion of the noncoding SOST-specific regulatory element, exhibited impaired limb bud 
development and syndactyly (33). This feature is observed in sclerosteosis patients with 
loss-of-function SOST mutations, but not in patients of Van Buchem’s disease in which the 
enhancer element involved in adult SOST expression is absent (5;7;86). Lastly, DMP1-
SOST transgenic mice overexpressing human Sost in osteocytes under the control of the 
DMP1–8kb promoter fragment showed a potent inhibition of bone formation and decreased 
bone mass in cancellous bone of the vertebra or the distal femur (12). However, no decreases 
in bone formation on periosteal or endocortical surfaces or changes in the geometry of 
cortical bone were observed in DMP1-SOST mice. Nevertheless, bone apposition on the 
periosteal surface of the ulnae in response to loading is blunted in DMP1-SOST mice (11), 
as it will be discussed below. Moreover, the increase in bone formation on both periosteal 
and endocortical surfaces induced by osteocytic PTH receptor signaling in DMP1-caPTHR 
transgenic mice is abolished in double transgenic mice also expressing the DMP1-SOST 
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transgene (12). These findings indicate that sclerostin is a potent negative regulator of bone 
formation and a critical mediator in the anabolic response of the skeleton to mechanical 
force and signaling activated by the PTH receptor in osteocytes.
Sost/sclerostin stimulates bone resorption
Osteoprotegerin (Opg), the decoy receptor for Rankl and thus inhibitor of bone resorption 
(88), is a Wnt/βcatenin target gene (1). Thus, genetic manipulation of Wnt/βcatenin 
signaling leads to marked changes in Opg expression with the consequent effects on 
resorption. Specifically, inactivation of Wnt/βcatenin in mature osteoblasts/osteocytes 
decreases Opg and increases osteoclast differentiation and bone resorption (89–91). 
Conversely, activation of Wnt/βcatenin in osteoblasts increases Opg expression and reduces 
bone resorption (89;90).
Because sclerostin antagonizes the Wnt/βcatenin signaling pathway, it is not unexpected that 
changes in Sost/sclerostin expression could also modulate resorption by regulating Opg. In 
fact, neutralizing anti-sclerostin antibodies increase bone formation and decrease bone 
resorption markers in experimental animals and humans, suggesting that the bone gain 
achieved results from the combination of enhanced bone formation and decreased bone 
resorption (92).
Consistent with this notion, overexpression of Sost in osteocytes exacerbate intracortical 
remodeling and the increase in osteoclasts displayed by DMP1-8kb-caPTHR1 mice (12). 
This enhanced bone resorption in double transgenic DMP1-8kb-caPTHR1/DMP1-SOST 
mice is accompanied by a marked decrease in Opg expression. In addition, overexpression 
of Sost in DMP1-SOST mice is sufficient to increased Rankl levels in bone (12;75). 
Activation of Wnt/βcatenin signaling in osteocytes in knockin daβcatOt mice also increases 
Opg and increases Rankl expression (75). However, in contrast to mice with activation of the 
pathway in osteoblasts, Rankl expression also increased and to a greater extent than Opg in 
daβcatOt mice, resulting in enhanced Rankl/Opg ratio, increased osteoclasts and elevated 
resorption (75). The increased in Rankl induced by activation of Wnt/βcatenin in osteocytes 
is driven by Sost/sclerostin production and neutralization of sclerostin activity abolished 
Rank increase displayed bone by daβcatOt mice (75). Moreover, Sost KO mice exhibit the 
expected increase in Opg but no changes in Rankl demonstrating that Sost expression is 
needed to increase Rankl by Wnt/βcatenin signaling (75). These results are in line with 
earlier findings indicating that recombinant sclerostin upregulates Rankl and increases 
osteoclast formation in vitro (93). This evidence supports the notion that sclerostin exhibits 
autocrine effects in osteocytes. The mechanisms underlying the regulation of Rankl 
expression by Sost/sclerostin in osteocytes remain to be determined.
Wnt/βcatenin signaling inhibits osteoclast formation directly by acting on osteoclast 
precursors, as knockout of βcatenin in these cells increases osteoclast number and enhances 
resorption (94). This evidence suggest that sclerostin might have a direct role on osteoclast 
differentiation that is independent of Rankl and Opg in osteoclast support cells. Furthermore, 
sclerostin upregulates in osteocytes in vitro the expression of cathepsin K, TRAP, and 
carbonic anhydrase-2, proteins involved in the remodeling of extracellular matrix 
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surrounding osteocytes (93). These findings suggest that sclerostin might also influence the 
release of mineral from bone in the process called osteocytic osteolysis.
Wnt/β-catenin-independent and non-skeletal actions of sclerostin
Previous work demonstrated that Sclerostin directly interacts with several members of the 
BMP and Wnt pathways such as BMP4, BMP2 and Lrp 4/5/6 (4;77;95;96). More recently, 
using a sclerostin affinity capture technique and mass spectrometry, it was shown that 
alkaline phosphatase, carbonic anhydrase, gremlin-1, fetuin A, midkine, annexin A1 and A2, 
and collagen α1, bind to sclerostin (97). Further, in this study, binding between sclerostin 
and other protein members of the Wnt signaling cascade such as casein kinase II and 
secreted frizzled related protein 4 was found. Thus, while inhibition of Wnt/β-catenin via 
interaction with Lrp4/5/6 appears to be the main mechanism of action of sclerostin, it is 
possible that interactions between sclerostin and other proteins in bone contribute to alter 
bone formation and resorption.
The lack of extraskeletal complications in sclerosteosis or van Buchem patients or after anti-
sclerostin therapy indicate that the main actions of sclerostin occur in the skeleton. However, 
several reports has suggested that sclerostin might also have non-skeletal actions. For 
instance, Sost deficiency induces B cells apoptosis potentially by inducing a decrease in the 
expression of the growth stimulating factor CXCL12 (98). Moreover, circulating sclerostin 
levels correlate with vascular calcifications in humans with and without renal disease; and 
sclerostin expression is found in areas with ectopic calcification (26;99). Moreover, 
treatment with anti-sclerostin in a mouse model of chronic kidney disease showed a trend 
towards reduction in calcification (100). However, whether sclerostin plays a role in 
vasculature calcification or its expression is simply a biomarker for valve calcification of 
remains to be seen. It has been also suggested that sclerostin regulates adipocyte 
differentiation and/or fat production. In fact, several studies show a positive correlation 
between the percentage of abdominal fat, gynoid fat, and fat mass (82;101;102); and in vitro 
studies demonstrate that sclerostin enhances adipocyte differentiation in 3T3-L1 cells (103). 
Further research is warranted to determine the potential role of Wnt-βcatenin-independent 
actions of sclerostin and to examine the therapeutic potential of pharmacological inhibition 
sclerostin in non-skeletal tissues.
4. ROLE OF SCLEROSTIN IN THE SKELETAL RESPONSE TO MECHANICAL 
STIMULATION
The abundance and strategic location of osteocytes makes them the most suitable candidate 
cells for detecting variations in strain and for distributing signals leading to adaptation of the 
skeleton to meet mechanical needs by changing its mass, shape, and microarchitecture 
(104;105). However, the molecular mediator(s) had remained elusive until it was 
demonstrated that mechanical loading decreases the expression of Sost/sclerostin in 
osteocytes, and that conversely, unloading increases it. Moreover, areas of cortical bone 
receiving greater strain stimuli and higher bone formation exhibit a greater reduction in the 
number of sclerostin-positive osteocytes and in the intensity of sclerostin staining per 
osteocyte (106). These findings support the notion that osteocytes coordinate the osteogenic 
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response to mechanical force by downregulating sclerostin, thereby locally unleashing Wnt 
signaling. Indeed, the osteogenic response to mechanical stimulation is disrupted in mice 
overexpressing in osteocytes a human SOST transgene that cannot be downregulated by 
loading (DMP1-SOST) (11). Thus, whereas WT mice showed the expected decrease in 
sclerostin expression in osteocytes and a robust and dose-dependent increased bone 
formation upon ulnae loading, DMP1-SOST mice exhibited an overall reduced sensitivity to 
mechanical stimulation. Moreover, loading increased the expression of several genes 
associated with activation of Wnt signaling in WT mice, whereas this effect was absent in 
DMP1-SOST mice (107;108). Thus, Sost/sclerostin downregulation is an obligatory step for 
mechanotransduction, and for activation of the Wnt pathway and the increase in bone 
formation induced by mechanical force.
5. ROLE OF SCLEROSTIN IN THE BONE ANABOLIC ACTIONS OF PTH
Osteocytes are crucial target cells for the skeletal actions of PTH as evidenced by the 
downregulation of Sost expression as well as the modulation by the hormone of the 
expression of several other osteocytic genes that impact skeletal homeostasis, including 
RANKL, FGF23, and OPG (42). This notion is supported by the evidence that mice lacking 
the PTH receptor in osteocytes exhibit impaired bone gain in response to intermittent PTH 
administration (42;109;110). Furthermore, the increase in bone formation exhibited by 
DMP1-8kb-caPTHR1 is abolished in double transgenic mice also overexpressing human 
SOST in osteocytes (DMP1-SOST), demonstrating the requirement of Sost downregulation 
for bone gain in this transgenic mouse model (111). Moreover, similar to daily injections of 
PTH, mechanical loading failed to increase cancellous and cortical bone mass and to 
downregulate Sost/sclerostin or stimulate Wnt/βcatenin signaling in mice lacking the PTH 
receptor in osteocytes. These findings suggested a potential role of osteocytes in bone 
anabolism induced by PTH through inhibition of Sost/sclerostin. Remarkably, however, PTH 
induced equivalent increases in cortical and cancellous bone mass, similar activation of 
canonical Wnt signaling, and increased bone forming activity of osteoblasts in DMP1-SOST 
compared to WT control littermates (112). The lack of requirement of Sost/sclerostin for 
PTH anabolic actions is in line with earlier studies showing normal or even enhanced 
response to anabolic regimens of PTH in Sost knockout mice (113). In contrast, Kramer et 
al. reported that PTH-induced bone gain is reduced in mice harboring the entire human 
SOST gene (BAC-SOST), including its regulatory elements, to systemically overexpress 
Sost (14;33). The discrepancy between the latter study and the findings with the DMP1-
SOST mice could be explained by the use of different transgenic mouse models, and the fact 
that the BAC-SOST transgene is still downregulated by PTH hindering the interpretation of 
the results. Thus, whereas the levels of the human SOST transgene remained unchanged by 
PTH administration to DMP1-SOST mice, they were reduced about 50% in PTH-treated 
BAC-SOST mice.
All together, these findings demonstrate that the osteocytic PTHR1 is central for the 
increased bone formation induced by PTH and mechanical loading; however, the molecular 
mediator(s) downstream PTHR1 signaling are different. Sost/sclerostin downregulation is 
required for the anabolic actions of mechanical loading, whereas Sost/sclerostin 
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downregulation is dispensable for the anabolic effects of PTH. Future studies are warranted 
to unravel alternative pathways activated by PTH in osteocytes that lead to bone anabolism.
6. ROLE OF SCLEROTIN IN THE BONE LOSS INDUCED BY 
GLUCOCORTICOIDS
Glucocorticoid excess is a leading cause of bone fragility worldwide (114), and the 
mechanisms activated by the hormone and how to interfere with its actions in bone are a 
matter of intense investigation. Recent findings demonstrate that glucocorticoids hinder the 
expression of target genes of the Wnt/βcatenin pathway, regardless of whether they are 
associated with bone anabolism (i.e. bone gain) or anti-catabolism (i.e. inhibition of bone 
loss) (56). This action of the hormone is exerted, at least in part, by increasing the expression 
of Sost/sclerostin. However, it is unclear whether this phenomenon is due to direct regulation 
of transcription of the Sost gene or to indirect mechanisms. Nevertheless, Sost/sclerostin 
deficiency protects against the loss of bone mass, deterioration of microarchitecture, and 
reduction of extrinsic/structural and intrinsic/material mechanical properties induced by 
glucocorticoids. Remarkably, however, the bone protective effect of Sost/sclerostin 
deficiency against glucocorticoids is not due to an opposing action to increase bone 
formation and maintain anabolic signaling. Instead, it is due to preservation of the Wnt/
βcatenin anti-catabolic cellular and molecular signature. Therefore, this pathway which is 
predominantly anabolic for bone is switched to anti-catabolic in the frame of glucocorticoid 
excess. These findings suggest that therapeutic interventions targeting sclerostin and 
activating Wnt/βcatenin signaling could effectively halt the high bone resorption responsible 
for the profound and rapid bone loss induced by glucocorticoids, which in humans can reach 
up to 12% during the first year of treatment (115).
Consistent with these findings in skeletally mature Sost/sclerostin deficient mice, 
pharmacologic inhibition of sclerostin with a neutralizing antibody opposed the lack of bone 
gain and the loss of strength induced by glucocorticoids in growing mice (116;117). 
Although it was proposed that these effects were due to preservation of osteoblast activity 
(117), mice treated with glucocorticoids and the anti-sclerostin antibody in these earlier 
studies exhibited lower circulating TRAP5b (116) or CTX-1 (117), but still markedly 
reduced bone formation markers osteocalcin and P1NP (116), compared to the 
corresponding mice treated with glucocorticoids alone. Likewise, sustained activation of the 
Wnt/βcatenin signaling in Sost deficient mice abolished the increase in resorption induced 
by glucocorticoids but not the decreased bone formation (56). Moreover, the decrease in 
Opg and increase the Rankl/Opg ratio induced by glucocorticoids is abolished in bones from 
Sost−/− mice or in WT bones treated with an anti-sclerostin antibody. Taking together, these 
findings demonstrate that Sost/sclerostin deficiency, either genetic or pharmacologically 
achieved, maintains bone mass and strength in conditions of glucocorticoid excess by 
inhibiting bone resorption, through sustained anti-catabolic signaling driven by Opg.
A clinical case reported that glucocorticoids stop the exaggerated bone gain and reduced the 
high circulating P1NP in a patient with Van Buchem disease, in which impaired production 
of sclerostin expression leads to continuous bone anabolism causing life-threatening 
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increased intracranial pressure (118). The findings that bone formation and Wnt/βcatenin 
anabolic signaling is still decreased in Sost/sclerostin deficient mice treated with 
glucocorticoids (56) provide a mechanistic explanation for these clinical findings. Taken 
together, these pieces of evidence demonstrate that glucocorticoids oppose the effects of 
Sost/sclerostin deficiency on bone formation in both humans and mice.
Another unwanted consequence of glucocorticoid excess, either endogenous or iatrogenic, is 
muscle weakness; which reduces body balance and, when combined with lower bone mass, 
increases the risk of bone fractures. Due to their intimate association as a mechanical unit, 
changes in bone could potentially impact skeletal muscle and vice versa. The mouse model 
of glucocorticoid excess faithfully reproduces the bone and skeletal muscle atrophy 
exhibited by humans (56). However, the bone preservation resulting from Sost/sclerostin 
deficiency did not protect from muscle atrophy; and conversely, the marked loss of muscle 
mass experienced by the Sost deficient mice did not translate into apparent detrimental 
effects on bone volume or mechanical properties. These findings demonstrate that Sost/
sclerostin deficiency protects exclusively bone, but not muscle, from the action of 
glucocorticoids, and show a lack of crosstalk between these two tissues in the frame of 
glucocorticoid-induced musculoskeletal atrophy. Future studies are warranted to investigate 
whether muscle-derived factors contribute to the low bone formation and high prevalence of 
osteoblast and osteocyte apoptosis still exhibited by Sost/sclerostin deficient mice treated 
with glucocorticoids
7. ROLE OF SCLEROSTIN (AND DKK1) AS NEGATIVE FEEDBACK 
INHIBITORS OF WNT SIGNALING-DRIVEN BONE FORMATION
We recently showed that genetic activation of βcatenin signaling in osteocytes increases 
bone formation and resorption leading to bone gain (75). Bone anabolism is achieved by 
enhancing osteoblast to osteocyte differentiation, and, consequently, the expression of 
osteocyte markers, including Sost/sclerostin and Dkk1, is increased. Similarly, the activation 
of Wnt/βcatenin signaling and increased bone formation exhibited by rodents receiving 
neutralizing antibodies against sclerostin is also accompanied by increased expression of 
both Sost and Dkk1 (92;119). Upregulation of the Wnt antagonists might temper the 
anabolic response triggered by activation of the pathway to protect from excessive bone gain 
and could explain at least partially the reduced anabolic potency that presents with 
prolonged sclerostin inhibition (92) and the decline of bone formation makers after each 
dose of anti-sclerostin antibody (120;121). Consistent with this notion, dual inhibition of 
sclerostin and Dkk-1 with a novel bispecific antibody results in greater increases bone 
formation when compared to neutralization of each of the Wnt antagonists alone (119). 
Taken together, these findings suggest that Sost and Dkk1 act as a negative feedback 
mechanism that limits Wnt-driven bone formation.
8. ROLE OF SOST/SCLEROSTIN IN MULTIPLE MYELOMA BONE DISEASE
In multiple myeloma (MM) increased numbers of monoclonal plasma cells in the bone 
marrow induce localized osteolytic lesions that rarely heal, due to increased bone resorption 
and suppressed bone formation (122;123). Serum sclerostin levels are elevated in MM 
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patients, which correlate with reduced osteoblast function and poor survival (124). Recent 
studies demonstrate that osteocytes contribute to MM generating a microenvironoment that 
is conducive to enhanced bone resorption and suppressed bone formation, and that 
osteocytes in mice bearing MM tumors express elevated Sost/sclerostin (125). Further, direct 
cell-to-cell contact with MM cells increases Sost/sclerostin expression in osteocytes and 
sclerostin accumulated in culture media decreases Wnt signaling and inhibits osteoblastic 
gene expression. Sost/sclerostin expression has also been detected in CD138+ cells from 
MM patients (30;31); and more recently it has been suggested that osteoblasts could also be 
a potential source of this protein in MM (22). Regardless of the cell source, recent findings 
suggest that blockade of Sost/sclerostin action could ameliorate MM bone disease. Thus, 
genetic deletion of the Sost gene prevented the bone loss and decreased osteocytic lesions in 
an immunodeficient/SCID MM model of MM (126). Moreover, administration of a 
neutralizing anti-sclerostin antibody reduced the development of osteolytic lesions and the 
decrease in circulating bone formation markers exhibited by immunocompetent mice with 
established MM (126). In these studies, Sost deficiency or pharmacological inhibition of 
sclerostin did not alter tumor burden. Similarly, pharmacologic inhibition of sclerostin 
reversed the osteolytic bone disease in a humanized MM xenograft mouse model bearing 
human MM cells, also without affecting tumor growth (22); and combination of anti-
sclerostin therapy with the anti-tumor drug Bortezomib decreased tumor burden and improve 
bone disease. Further, simultaneous injection of MM cells together with an anti-sclerostin 
antibody prevented the development of MM bone disease and suppressed tumor growth 
(127). Future research is warranted to identify the factors involved in the dysregulation of 
Sost/sclerostin in MM and the mechanisms underlying the protective effects on bone of 
inhibition of sclerostin in these preclinical models of MM and to develop therapeutic 
approaches based on pharmacological inhibition of sclerostin in combination with other anti-
tumor drugs to synergistically decrease MM growth and prevent bone disease.
In addition, sclerostin may play a role in other cancers that grow in bone, as patients with 
prostate cancer exhibit high serum sclerostin levels compared to healthy subjects (128); and 
breast cancer cells have been reported to produce sclerostin and inhibit osteoblast 
differentiation (129). Thus, future studies are also needed to investigate the contribution of 
sclerostin to other cancers that grown in bone and weaken the skeleton.
9. CONCLUSION AND FUTURE DIRECTIONS
Advances during the last decade provided relevant information on the regulation of Sost/
sclerostin and its mechanism(s) of action. Several stimuli have been reported to regulate 
Sost/Sclerostin expression, however how these factors interplay to regulate the expression of 
this gene in a spatiotemporal manner is unknown. Animal studies demonstrate that sclerostin 
is key for skeletal homeostasis, and required for the bone anabolic response to mechanical 
loading although appears dispensable for PTH-induced bone gain. The knowledge provided 
by preclinical investigations resulted into clinical trials based on the neutralization of 
sclerostin activity as novel osteoanabolic therapeutic approach (130–133). It is now clear 
that sclerostin is capable of uncoupling bone formation and bone resorption, by inhibiting 
osteoblast function while stimulating osteoclast function, as the bone gain achieved by 
pharmacologic inhibition of sclerostin results from stimulation of osteoblast activity and 
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inhibition of bone resorption. Furthermore, the recent observations show that activation of 
βcatenin in osteocytes increases bone resorption and Rankl production in a sclerostin-
dependent manner. Anti-sclerostin therapy has shown beneficial skeletal outcomes in 
osteoporotic patients, however more recent evidence shows that the anabolic effects of this 
therapy attenuate with time and that after discontinuation BMD returns to pretreatment 
levels over time. The new evidence showing increased levels of Sost/sclerostin (and Dkk1) 
after activation of Wnt-βcatenin signaling suggest that sclerostin (and Dkk1) act as a 
negative feedback limiting bone formation stimulated by this pathway. Preclinical models 
demonstrate that sclerostin production is also altered in cancers that grow in bone and that 
its inhibition prevents cancer-induced bone loss, raising the possibility of using neutralizing 
antibodies against sclerostin as new therapeutic approach for cancers that target bone. Future 
studies are required to identify the exact source of sclerostin, the events leading to its 
aberrant production in skeletal pathologies, the mechanisms underlying its actions on 
osteoblasts and osteoclasts, and its autocrine effects on osteocytes. Full understanding of the 
biology and pathophysiology of sclerostin will lead to improved current therapies and the 
identification of novel targets to treat skeletal diseases.
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HIGHLIGHTS
• Sclerostin is a key molecular coordinator of both bone formation and bone 
resorption.
• Binding to the chaperone LRP4 and the co-receptors of canonical Wnt 
signaling LRP5 and 6 and the consequent inhibition of Wnt/βcatenin 
signaling mediates the skeletal actions of sclerostin.
• Sost/sclerostin expression is regulated by complex mechanisms that involve 
crosstalk between hormones and mechanical stimuli, through activation of 
transcription factors and chromatin epigenetic modifications.
• Sost/sclerostin expression is altered during aging, in several skeletal diseases 
and cancers that grow in bone.
• Genetic and pharmacologic inhibition of Sost/sclerostin expression markedly 
affects skeletal homeostasis resulting from potent stimulation of bone 
formation and inhibition of bone resorption.
• Identification of the exact factors controlling Sost/Sclerostin expression and 
full understanding of the mechanisms of action of this gene/protein will 
provide the basis for developing new therapeutic strategies to treat bone 
diseases.
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Figure 1. Role and mechanism of action of Sost/sclerostin in bone
The expression of Sost/sclerostin is tightly regulated by complex mechanisms involving 
crosstalk between systemic hormones, cytokines and mechanical stimuli (black lines). The 
chaperone LRP4 presents sclerostin to the Wnt co-receptors LRP5/6, thus facilitating 
sclerostin inhibition of Wnt/βcatenin signaling. The consequent inhibition of the Wnt/
βcatenin pathway leads to decreased bone formation due to impaired osteoblastogenesis and 
decreased osteoblast survival (green line). Novel findings suggest that activation of 
osteocytic Wnt/βcatenin signaling itself increases the expression of Sost/sclerostin, which in 
turn acts in a negative feedback limiting bone formation driven by the pathway. Sclerostin 
not only regulates bone formation, but also bone resorption (blue lines). Inhibition of Wnt/
βcatenin signaling in osteoblasts and osteocytes decreases the expression of Opg, and direct 
actions of sclerostin on osteocytes increase the expression of RANKL. In addition, inhibition 
of Wnt/βcatenin signaling in osteoclast precursors directly favors their differentiation. Thus, 
by antagonizing Wnt/βcatenin signaling, sclerostin has the potential to stimulate osteoclast 
differentiation and enhance bone resorption. Further, sclerostin increases in osteocytes the 
expression and activity of enzymes that remodel perilacunar matrix leading to osteolytic 
osteolysis.
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